SFOSF (Shanghai Fosun Pharmaceutical (Group) Co) Net Income (Continuing Operations): $621 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SFOSF Shanghai Fosun Pharmaceutical (Group) Co Ltd SFOSF
76 GF Score
Price $2.20
GF Value $2.80
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Net Income (Continuing Operations)?

Shanghai Fosun Pharmaceutical (Group) Co SFOSF 76 Net Income (Continuing Operations) is $621 Mil as of Mar. 2026. GuruFocus rates SFOSF with a GF Score™ of 76/100 and a GF Value™ of $2.80 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shanghai Fosun Pharmaceutical (Group) Co's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was $157 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was $621 Mil.

Shanghai Fosun Pharmaceutical (Group) Co  (OTCPK:SFOSF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Shanghai Fosun Pharmaceutical (Group) Co Net Income (Continuing Operations) Related Terms

Shanghai Fosun Pharmaceutical (Group) Co Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Net Income (Continuing Operations) Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 781.29 566.21 405.46 482.43 603.13

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.88 161.36 134.19 169.22 156.65
SFOSF
76GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SFOSF
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $621 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $621 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Net Income (Continuing Operations) of $621 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Net Income (Continuing Operations) too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (Continuing Operations) is $621 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Net Income (Continuing Operations) compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Net Income (Continuing Operations) of $621 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (Continuing Operations) is $621 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.80, compared to a current price of $2.20 — trading 21.4% below its estimated fair value. The current Net Income (Continuing Operations) is $621 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Net Income (Continuing Operations) is $621 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of $2.20 is trading 21.4% below its estimated GF Value™ of $2.80. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SFOSF:

  • Net Income (Continuing Operations): $621 Mil
  • GF Value™: $2.80 vs. price of $2.20 (21.4% below fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score

Get the complete analysis for SFOSF

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$2.80
GF Value